Hodson R. Alzheimer’s disease. Nature. 2018;559:S1. https://doi.org/10.1038/d41586-018-05717-6

Article  CAS  PubMed  Google Scholar 

Simon L, Chloé B, Weidner W. World Alzheimer report 2023: reducing dementia risk: never too early, never too late. London, England: Alzheimer’s Disease International; 2023. https://www.alzint.org/u/World-Alzheimer-Report-2023

Google Scholar 

Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease. Curr Neuropharmacol. 2020;18:1106–25. https://doi.org/10.2174/1570159X18666200528142429

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sang Z, Wang K, Dong J, Tang L. Alzheimer’s disease: updated multi-targets therapeutics are in clinical and in progress. Eur J Med Chem. 2022;238:114464. https://doi.org/10.1016/j.ejmech.2022.114464

Article  CAS  PubMed  Google Scholar 

Zhang P, Xu S, Zhu Z, Xu J. Multi-target design strategies for the improved treatment of Alzheimer’s disease. Eur J Med Chem. 2019;176:228–47. https://doi.org/10.1016/j.ejmech.2019.05.020

Article  CAS  PubMed  Google Scholar 

Kumar B, Thakur A, Dwivedi AR, Kumar R, Kumar V. Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer’s disease. Curr Med Chem. 2022;29:1757–803. https://doi.org/10.2174/0929867328666210512005508

Article  CAS  PubMed  Google Scholar 

Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141:1917–33. https://doi.org/10.1093/brain/awy132

Article  PubMed  PubMed Central  Google Scholar 

Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer’s disease. Eur J Med Chem. 2017;132:294–309. https://doi.org/10.1016/j.ejmech.2017.03.062

Article  CAS  PubMed  Google Scholar 

Xing S, Li Q, Xiong B, Chen Y, Feng F, Liu W, et al. Structure and therapeutic uses of butyrylcholinesterase: application in detoxification, Alzheimer’s disease, and fat metabolism. Med Res Rev. 2021;41:858–901. https://doi.org/10.1002/med.21745

Article  CAS  PubMed  Google Scholar 

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5. https://doi.org/10.1126/science.1566067

Article  CAS  PubMed  Google Scholar 

Fedele E. Anti-amyloid therapies for Alzheimer’s disease and the amyloid cascade hypothesis. Int J Mol Sci. 2023;24:14499. https://doi.org/10.3390/ijms241914499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8:248. https://doi.org/10.1038/s41392-023-01484-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:472932. https://doi.org/10.1155/2012/472932

Article  PubMed  PubMed Central  Google Scholar 

Plascencia-Villa G, Perry G. Preventive and therapeutic strategies in Alzheimer’s disease: focus on oxidative stress, redox metals, and ferroptosis. Antioxid Redox Signal. 2021;34:591–610. https://doi.org/10.1089/ars.2020.8134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Habtemariam S. Protective effects of caffeic acid and the Alzheimer’s brain: an update. Mini Rev Med Chem. 2017;17:667–74. https://doi.org/10.2174/1389557516666161130100947

Article  CAS  PubMed  Google Scholar 

Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease. CNS Neurosci Ther. 2011;17:411–27. https://doi.org/10.1111/j.1755-5949.2010.00161.x

Article  CAS  PubMed  Google Scholar 

Desai AK, Grossberg GT. Rivastigmine for Alzheimer’s disease. Expert Rev Neurother. 2005;5:563–80. https://doi.org/10.1586/14737175.5.5.563

Article  CAS  PubMed  Google Scholar 

Zhang H, Wang Y, Wang Y, Li X, Wang S, Wang Z. Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer’s disease. Eur J Med Chem. 2022;240:114606. https://doi.org/10.1016/j.ejmech.2022.114606

Article  CAS  PubMed  Google Scholar 

Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents. Arh Hig Rada Toksikol. 2020;71:285–99. https://doi.org/10.2478/aiht-2020-71-3466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sang Z, Wang K, Bai P, Wu A, Shi J, Liu W, et al. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;194:112265. https://doi.org/10.1016/j.ejmech.2020.112265

Article  CAS  PubMed  Google Scholar 

Sang Z, Wang K, Shi J, Cheng X, Zhu G, Wei R, et al. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;187:111958. https://doi.org/10.1016/j.ejmech.2019.111958

Article  CAS  PubMed  Google Scholar 

Sang Z, Wang K, Shi J, Liu W, Cheng X, Zhu G, et al. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;192:112180. https://doi.org/10.1016/j.ejmech.2020.112180

Article  CAS  PubMed  Google Scholar 

Manzoor S, Gabr MT, Nafie MS, Raza MK, Khan A, Nayeem SM, et al. Discovery of quinolinone hybrids as dual inhibitors of acetylcholinesterase and abeta aggregation for Alzheimer’s disease therapy. ACS Chem Neurosci. 2024;15:539–59. https://doi.org/10.1021/acschemneuro.3c00588

Article  CAS  PubMed  Google Scholar 

Manzoor S, Prajapati SK, Majumdar S, Raza MK, Gabr MT, Kumar S, et al. Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer’s action: design, synthesis, crystal structure and in-vitro biological evaluation. Eur J Med Chem. 2021;215:113224. https://doi.org/10.1016/j.ejmech.2021.113224

Article  CAS  PubMed  Google Scholar 

Dighe SN, Deora GS, De la Mora E, Nachon F, Chan S, Parat MO, et al. Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem. 2016;59:7683–9. https://doi.org/10.1021/acs.jmedchem.6b00356

Article  CAS  PubMed  Google Scholar 

Sang Z, Qiang X, Li Y, Yuan W, Liu Q, Shi Y, et al. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2015;94:348–66. https://doi.org/10.1016/j.ejmech.2015.02.063

Article  CAS  PubMed  Google Scholar 

Digiacomo M, Chen Z, Wang S, Lapucci A, Macchia M, Yang X, et al. Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD. Bioorg Med Chem Lett. 2015;25:807–10. https://doi.org/10.1016/j.bmcl.2014.12.084

Article  CAS  PubMed  Google Scholar 

Manzoor S, Almarghalani DA, James AW, Raza MK, Kausar T, Nayeem SM, et al. Synthesis and pharmacological evaluation of novel triazole-pyrimidine hybrids as potential neuroprotective and anti-neuroinflammatory agents. Pharm Res. 2023;40:167–85.